Literature DB >> 15222772

What place does naltrexone have in the treatment of alcoholism?

Damaris J Rohsenow1.   

Abstract

Despite two recent negative trials, most controlled clinical studies have found that when naltrexone is added to substance abuse treatment or counselling, significantly less heavy drinking is done by the patients who are willing to take most of the prescribed naltrexone. Naltrexone also reduces urges to drink and makes any slips back into drinking less pleasant. Therefore, naltrexone can be a useful adjunct to substance abuse counselling or rehabilitation programmes, as one of many tools that clinicians and patients use. However, beneficial effects are limited in scope. Naltrexone mostly does not increase the chance of staying completely abstinent but rather reduces the intensity or frequency of any drinking that does occur. Many alcohol-dependent individuals are medically ineligible or are unwilling to take naltrexone, many who start naltrexone do not continue with it and many who comply with it do not benefit. Compliance is greater for individuals who experience fewer adverse effects and who have stronger beliefs in the benefits of naltrexone, suggesting that clinicians can increase compliance by helping patients to manage adverse effects and by bolstering patients' beliefs in the benefits of naltrexone. Alcohol-dependent individuals who are most likely to benefit from naltrexone seem to be those with close relatives who also had alcohol problems, or who have stronger urges to drink or who are more limited in cognitive abilities. Some individuals may benefit from a higher dose, particularly people with lower blood concentrations of the medication, and individuals who achieve good results may benefit from a longer course of treatment with naltrexone. In these ways, treatment can be targeted to increase the likelihood of beneficial outcomes with naltrexone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15222772     DOI: 10.2165/00023210-200418090-00001

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  36 in total

Review 1.  Clinical trials in psychiatry: should protocol deviation censor patient data?

Authors:  P W Lavori
Journal:  Neuropsychopharmacology       Date:  1992-01       Impact factor: 7.853

2.  Current problems and future challenges in randomized clinical trials.

Authors:  A R Feinstein
Journal:  Circulation       Date:  1984-11       Impact factor: 29.690

3.  Naltrexone for alcohol dependence: a randomized controlled trial.

Authors:  P L Morris; M Hopwood; G Whelan; J Gardiner; E Drummond
Journal:  Addiction       Date:  2001-11       Impact factor: 6.526

4.  Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study.

Authors:  Markus Gastpar; Udo Bonnet; Jobst Böning; Karl Mann; Lutz G Schmidt; Michael Soyka; Tilman Wetterling; Volker Kielstein; Dominic Labriola; Robert Croop
Journal:  J Clin Psychopharmacol       Date:  2002-12       Impact factor: 3.153

5.  Naltrexone and alcohol dependence. Role of subject compliance.

Authors:  J R Volpicelli; K C Rhines; J S Rhines; L A Volpicelli; A I Alterman; C P O'Brien
Journal:  Arch Gen Psychiatry       Date:  1997-08

6.  Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching.

Authors:  A J Jaffe; B Rounsaville; G Chang; R S Schottenfeld; R E Meyer; S S O'Malley
Journal:  J Consult Clin Psychol       Date:  1996-10

7.  Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence.

Authors:  A C King; J R Volpicelli; A Frazer; C P O'Brien
Journal:  Psychopharmacology (Berl)       Date:  1997-01       Impact factor: 4.530

8.  Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes.

Authors:  P M Monti; D J Rohsenow; R M Swift; S B Gulliver; S M Colby; T I Mueller; R A Brown; A Gordon; D B Abrams; R S Niaura; M K Asher
Journal:  Alcohol Clin Exp Res       Date:  2001-11       Impact factor: 3.455

9.  Sustained-release naltrexone for alcoholism treatment: a preliminary study.

Authors:  H R Kranzler; V Modesto-Lowe; E S Nuwayser
Journal:  Alcohol Clin Exp Res       Date:  1998-08       Impact factor: 3.455

10.  Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot feasibility study.

Authors: 
Journal:  Alcohol Clin Exp Res       Date:  2003-07       Impact factor: 3.455

View more
  10 in total

Review 1.  Extended-release intramuscular naltrexone in alcohol dependence in adults: profile report.

Authors:  Tracy Swainston Harrison; Greg L Plosker; Susan J Keam
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 2.  Extended-release intramuscular naltrexone.

Authors:  Tracy Swainston Harrison; Greg L Plosker; Susan J Keam
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Investigating Methamphetamine Craving Using the Extinction-Reinstatement Model in the Rat.

Authors:  Peter R Kufahl; M Foster Olive
Journal:  J Addict Res Ther       Date:  2011-11-15

4.  Motivational interviewing versus brief advice for cigarette smokers in residential alcohol treatment.

Authors:  Damaris J Rohsenow; Rosemarie A Martin; Peter M Monti; Suzanne M Colby; Anne M Day; David B Abrams; Alan D Sirota; Robert M Swift
Journal:  J Subst Abuse Treat       Date:  2013-10-14

5.  Effects of naltrexone on cortisol levels in heavy drinkers.

Authors:  Lara A Ray; James Mackillop; Lorenzo Leggio; Marilee Morgan; Kent E Hutchison
Journal:  Pharmacol Biochem Behav       Date:  2008-09-13       Impact factor: 3.533

6.  The delta(1) opioid receptor is a heterodimer that opposes the actions of the delta(2) receptor on alcohol intake.

Authors:  Richard M van Rijn; Jennifer L Whistler
Journal:  Biol Psychiatry       Date:  2009-07-03       Impact factor: 13.382

7.  Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.

Authors:  Jennifer W Tidey; Peter M Monti; Damaris J Rohsenow; Chad J Gwaltney; Robert Miranda; John E McGeary; James MacKillop; Robert M Swift; David B Abrams; Saul Shiffman; Jean A Paty
Journal:  Alcohol Clin Exp Res       Date:  2007-11-20       Impact factor: 3.455

8.  Extended naltrexone and broad spectrum treatment or motivational enhancement therapy.

Authors:  Richard Longabaugh; Philip W Wirtz; Suzy Bird Gulliver; Dena Davidson
Journal:  Psychopharmacology (Berl)       Date:  2009-07-29       Impact factor: 4.530

9.  Compliance with pharmacotherapy and direct healthcare costs in patients with Parkinson's disease: a retrospective claims database analysis.

Authors:  Florent F Richy; Guilhem Pietri; Kimberly A Moran; Emmanuelle Senior; Lydia E Makaroff
Journal:  Appl Health Econ Health Policy       Date:  2013-08       Impact factor: 2.561

10.  Misuse of Psychologically Active Substances of Convicts being in Prisons and their Treatment.

Authors:  Safuadan Plojovic; Slavica Dimitrijevic; Andrijana Maksimovic; Sabina Zejnelagic; Adem Hurem; Muamer Muraspahic
Journal:  Open Access Maced J Med Sci       Date:  2015-12-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.